The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy.
 
Mari Nakazawa
No Relationships to Disclose
 
Zeal Kamdar
No Relationships to Disclose
 
Amy Thomas
No Relationships to Disclose
 
Jennifer N. Durham
No Relationships to Disclose
 
Julie Nauroth
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Brian H. Ladle
No Relationships to Disclose
 
Steven Dykstra
Consulting or Advisory Role - Dracen
Patents, Royalties, Other Intellectual Property - Formulation Patent Pending for DRP-104 for Subcutaneous Injection
 
Margaret Dugan
Employment - Dracen
Leadership - Dracen
Stock and Other Ownership Interests - Dracen
Consulting or Advisory Role - Dracen
Travel, Accommodations, Expenses - Dracen
 
Francois Lafleur
Employment - Dracen
Leadership - Dracen
Stock and Other Ownership Interests - Dracen
Consulting or Advisory Role - Dracen
Travel, Accommodations, Expenses - Dracen
 
Mark E. Furth
No Relationships to Disclose
 
Robert D. Leone
No Relationships to Disclose
 
Elizabeth M. Jaffee
Consulting or Advisory Role - ABMETA Therapeutics; Achilles Therapeutics; Adventris; Break Through Cancer; Bristol Myers Squibb Foundation; Genentech; Lucence Diagnostics
Research Funding - Break Through Cancer; Bristol-Myers Squibb; CPRIT; Dragonfly Therapeutics; GE Healthcare; Genentech; HDT Bio; Lucence Diagnostics; Parker Institute for Cancer Immunotherapy; SURGE Therapeutics
Patents, Royalties, Other Intellectual Property - Royalties from publications - Elsiever; Vaccine patent applications
Other Relationship - ABMETA Therapeutics; Achilles Therapeutics; Adventris; CPRIT; Dragonfly Therapeutics; HDT Bio; Lucence Diagnostics; Parker Institute for Cancer Immunotherapy; SURGE Therapeutics
 
Mark Yarchoan
Leadership - Adventris Pharmaceuticals
Stock and Other Ownership Interests - Adventris Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Marina Baretti
Consulting or Advisory Role - Exelixis; Incyte